Latest Report Details Of Chemotherapy Induced Neutropenia – Pipeline Review, H2 2016


“The Report Chemotherapy Induced Neutropenia – Pipeline Review, H2 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Global Markets Directs, Chemotherapy Induced Neutropenia – Pipeline Review, H2 2016, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at :


– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

– The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chemotherapy Induced Neutropenia Overview 10

Therapeutics Development 11

Pipeline Products for Chemotherapy Induced Neutropenia – Overview 11

Pipeline Products for Chemotherapy Induced Neutropenia – Comparative Analysis 12

Chemotherapy Induced Neutropenia – Therapeutics under Development by Companies 13

Chemotherapy Induced Neutropenia – Therapeutics under Investigation by Universities/Institutes 16

Chemotherapy Induced Neutropenia – Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Chemotherapy Induced Neutropenia – Products under Development by Companies 21

Chemotherapy Induced Neutropenia – Products under Investigation by Universities/Institutes 23

Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 24

Apotex Inc. 24

Biocon Limited 25

Biogenomics Limited 26

Bolder Biotechnology, Inc. 27

Cellerant Therapeutics, Inc. 28

Chong Kun Dang Pharmaceutical Corp. 29

Cinfa Biotech S.L. 30

Dr. Reddy’s Laboratories Limited 31

Gene Techno Science Co., Ltd. 32

Generon (Shanghai) Corporation Ltd. 33

Genexine, Inc. 34

Hanmi Pharmaceuticals, Co. Ltd. 35

Myelo Therapeutics GmbH 36

Octapharma AG 37

Pfenex Inc. 38

Pfizer Inc. 39

Reliance Life Sciences Pvt. Ltd. 40

Richter Gedeon Nyrt. 41

Sandoz International GmbH 42

USV Limited 43

Chemotherapy Induced Neutropenia – Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Target 45

Assessment by Mechanism of Action 47

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

BBT-007 – Drug Profile 53

Product Description 53

Mechanism Of Action 53

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074